The ability of ketamine administration to activate prefrontal glutamate neurotransmission is thought to be a key mechanism contributing to its transient psychotomimetic effects and its delayed and sustained antidepressant effects. Rodent studies employing carbon-13 magnetic resonance spectroscopy ( 13 C MRS) methods have shown ketamine and other N-methyl-D-aspartate (NMDA) receptor antagonists to transiently increase measures reflecting glutamate-glutamine cycling and glutamate neurotransmission in the frontal cortex. However, there are not yet direct measures of glutamate neurotransmission in vivo in humans to support these hypotheses. The current first-level pilot study employed a novel prefrontal 13 C MRS approach similar to that used in the rodent studies for direct measurement of ketamine effects on glutamate-glutamine cycling. Twenty-one participants (14 healthy and 7 depressed) completed two 13 C MRS scans during infusion of normal saline or subanesthetic doses of ketamine. Compared to placebo, ketamine increased prefrontal glutamate-glutamine cycling, as indicated by a 13% increase in 13 C glutamine enrichment (t = 2.4, p = 0.02). We found no evidence of ketamine effects on oxidative energy production, as reflected by 13 C glutamate enrichment. During ketamine infusion, the ratio of 13 C glutamate/glutamine enrichments, a putative measure of neurotransmission strength, was correlated with the Clinician-Administered Dissociative States Scale (r = −0.54, p = 0.048). These findings provide the most direct evidence in humans to date that ketamine increases glutamate release in the prefrontal cortex, a mechanism previously linked to schizophrenia pathophysiology and implicated in the induction of rapid antidepressant effects. , as well as to develop glutamate-based "antipsychotics" to treat the often resistant cognitive deficits and negative symptoms in schizophrenia [5, 6] .
INTRODUCTION
The discovery [1] and replication [2] of the antidepressant effects of ketamine, and the implication of N-methyl-D-aspartate receptor (NMDAR) hypofunction in the pathophysiology of schizophrenia [3] have generated considerable excitement about the potential of targeting glutamate neurotransmission to develop safe, effective, and rapid acting antidepressants (RAADs) [4] , as well as to develop glutamate-based "antipsychotics" to treat the often resistant cognitive deficits and negative symptoms in schizophrenia [5, 6] .
However, to date not a single RAAD or glutamate-based antipsychotic has been approved to treat depression or schizophrenia, although two decades have passed since the RAAD and psychotomimetic effects of ketamine were first reported in the 1990s [3, 7] . A major obstacle in this field is the lack of biomarkers that directly reflect synaptic glutamate neurotransmission. Such markers would serve to (1) test ketamine's RAAD and psychotomimetic mechanisms in humans and (2) permit expedited screening and optimization of putative novel glutamate-based RAAD and antipsychotic agents.
Carbon-13 magnetic resonance spectroscopy ( 13 C MRS) is a unique, noninvasive method to measure neurotransmitter cycling and cell-specific neuroenergetics [8] [9] [10] . In the current study, we implemented a 13 C MRS pharmacoimaging paradigm, using a novel method [11] [12] [13] to conduct quantitative 13 C MRS acquisition in the human frontal lobe-a region closely related to psychopathology that was not initially accessible in 13 C MRS studies. We aimed to determine ketamine's effect on glutamate-glutamine cycling and to investigate the association between changes in neurotransmission and the psychotomimetic effects of ketamine. 13 C MRS is presently the only method that provides direct dynamic measurements of glutamate-glutamine cycling in the human brain [10] . Briefly, labeled 13 C-glucose is infused intravenously over 120 min during the MRS acquisition. The incorporation of the 13 C in glutamate and glutamine generates unique signals on the 13 C spectrum (Fig. 1) . Metabolites of 13 C-glucose enter the tricarboxylic acid (TCA; also known as Krebs) cycle, which in turn label glutamate. Then, as 13 C-glutamate is released into the synaptic cleft, astrocytes take it up and convert it to 13 C-glutamine (Fig. 2) . The glutamate and glutamine 13 C enrichments rise rapidly in the first 20-30 min of 13 C-glucose infusion and reach a steadystate in the last 40-60 min (Fig. S1) . Accordingly, the glutamate enrichment primarily reflects oxidative energy production through the TCA cycle, while the rate of glutamine enrichment primarily reflects glutamate neurotransmitter cycling [8, 10] .
A main limitation of previous methods is the lack of distinction between presynaptic glutamate release and postsynaptic activation, the latter has been related to the RAAD effects of ketamine [14, 15] . While these processes are highly coupled under normal conditions, preclinical 13 C MRS data suggest disproportionate changes following ketamine administration [16, 17] . In particular, approximately 9 min after intraperitoneal injection in rodents, ketamine induces a rise in prefrontal 13 C glutamine enrichment (~20%) with no changes in 13 C glutamate (~1%) [17] , suggesting a disproportionate change in neuroenergetics (V TCA ) vs. glutamate cycling (V cycle )-i.e., an alteration in neuronal energy-per-cycle (EPC) ratio. By 18 min after the injection, both prefrontal 13 C glutamate (~13%) and glutamine (~35%) enrichment increased [17] . Under normal conditions, neuronal energy largely supports postsynaptic neuronal activation and functional increments are consistently proportional to changes in glutamate-glutamine cycling, resulting in a largely constant EPC ratio across species and functional conditions [18, 19] . The alteration of EPC acutely post injection may reflect a transient reduction in postsynaptic activation [9] due to blockade of postsynaptic NMDAR by ketamine and its metabolite, norketamine. Thus, an alteration of EPC immediately post ketamine injection (i.e., an increase in presynaptic release without proportionate increase in postsynaptic activation) would be consistent with the NMDAR hypofunction model of schizophrenia, raising the question whether EPC, as reflected by 13 C glutamate/glutamine ratio, would predict the psychotomimetic effects of ketamine during infusion in humans. Consistent with this hypothesis, the increase in 13 C glutamate/ glutamine ratio in rodents is more evident following the administration of low doses of ketamine (3 and 10 mg/kg), selective NMDAR subtype 2B antagonist, and scopolamine-all of which are expected to have lower psychotomimetic effects compared to 30 mg/kg of ketamine. This possibility, if confirmed, would signify a paradigm shift suggesting that the behavioral disturbances during ketamine infusion may be driven by a loss of communication fidelity between presynaptic neurotransmission release and postsynaptic activation, rather than a correlate only of increased glutamate neurotransmission. Considering that the RAAD effects are associated with postsynaptic glutamate activation, the EPC biomarker will also provide a mechanism through which novel drugs may induce RAAD effects without psychotomimetic symptoms, provided that these new agents equally increase presynaptic release and postsynaptic activation.
In the current study, we primarily aimed to implement a novel, complex yet unique, pharmacoimaging paradigm to translate the preclinical 13 C MRS ketamine findings into a biomarker to apply in humans in vivo, investigating its potential utility in rational drug C]-glucose. Color code: blue-raw; red-fitted; green-residual. Abbreviations: GluC45 13 C-Glutamate C45, GlnC45 13 C-Glutamine C45, and AspC34 13 C-Aspartate C34 Fig. 2 Carbon-13 ( 13 C) labeling of glutamate and glutamine via the TCA and glutamate-glutamine cycle. Following glycolysis, 13 CGlucose ( 13 C-Glc) metabolites (i.e., acetyl-CoA) enter the mitochondrial tricarboxylic acid (TCA) cycle (also known as Krebs cycle) and subsequently label glutamate through exchange with α-ketoglutarate. Next, 13 C-glutamate is released into the synaptic cleft and taken up by astrocytes, where the 13 C-glutamate is converted to 13 C-glutamine and transferred to neurons. Hence, the rate of 13 Cglutamate enrichment is primarily affected by neuroenergetics (the neuronal TCA cycle) and the rate of 13 C-glutamine enrichment primarily reflects the rate of glutamate-glutamine cycling. The development of this metabolic model and potential impact of other metabolic pathways on the measured labeling are discussed in reference [10] . The figure was adapted with permission from the Emerge Research Program (emerge.care) development for mood and psychotic disorders, as well as for a variety of other potential neuropsychiatric indications. Additionally, considering recent preclinical evidence, we tested the hypothesis that ketamine in a cohort of healthy and depressed subjects would induce a large increase in prefrontal 13 C glutamine enrichment, with a modest increase in 13 C glutamate enrichment comparable to recent preclinical findings [17] . Increased 13 Cglutamine enrichment could be interpreted as a ketamineinduced surge in glutamate-glutamine cycling, and a rise in 13 C glutamate enrichment would suggest an acute increase in prefrontal oxidative energy. Based on findings from glutamate inhibitor studies [20] [21] [22] [23] , we predicted a positive association between glutamate-glutamine cycling and the behavioral psychotomimetic symptoms following ketamine administration. We also examined whether variability in 13 C glutamate/glutamine ratio, a putative indicator of EPC, would be associated with the psychotomimetic effects of ketamine as suggested by preclinical data.
METHODS

Study population
Twenty-four participants [17 healthy and 7 major depressive disorder (MDD)] between the age of 21 and 65 years were recruited for this study. Of the healthy subjects, one subject did not complete the second scan, and two subjects had unsuccessful scans. Subjects completed an informed consent process and were screened for study inclusion and exclusion criteria. For all participants, exclusion criteria consisted of medical conditions that contraindicate MRS or increase the risks of ketamine administration. A negative drug test, and for women, a negative pregnancy test and use of a medically accepted means of contraception were required. Healthy participants were excluded if they had a lifetime history of any psychiatric disorder, or if they had a first-degree relative with mood, anxiety, or psychotic disorder. MDD participants were included if they met the following study criteria: (1) current MDD as determined by a structured interview; (2) Montgomery-Åsberg Depression Rating Scale (MADRS) severity of 18 or more at baseline; (3) no substance abuse or dependence in the previous 12 months; (4) no lifetime history of psychosis or bipolar disorder; and (5) medication-free or on a stable (>4 weeks) antidepressant treatment. The MDD group was included in the current report to explore the possibility of differences between the two groups and to test the feasibility of conducting the 13 C MRS pharmacoimaging paradigm in this population. The target sample for the MDD group is 18 subjects, which will be reported in the future once enrollment is completed.
Overview of study design Two 13 C MRS scans, separated by at least 1 week, were performed using a single-blind, placebo-controlled, fixed-order within-subject design (Fig. S2) . On day 1, participants received normal saline and uniformly 13 C-labeled glucose infused over 120 min as described previously [24] . Concurrently, 13 C MRS of the frontal brain region was used to observe glutamate and glutamine 13 C enrichments during the placebo infusion. On day 8+, healthy participants received a subanesthetic dose that has been commonly used in studies examining the psychotomimetic effects of the drug (0.23 mg/kg bolus followed by 0.58 mg/kg infusion over approximately 75 min). This dose was administered to ensure rapid and robust psychotomimetic effect [25, 26] , which we believed would enhance statistical power to ascertain the relationship between glutamate cycling and the psychotomimetic symptoms during ketamine infusion. MDD patients received the dose most commonly used in depression clinical trials (0.5 mg/kg infused over 40 min) [1, 2] , concurrently with otherwise identical 13 Cglucose infusion and 13 C MRS scans. The psychotomimetic effects of ketamine were assessed using the Clinician-Administered Dissociative States Scale (CADSS) and Brief Psychiatric Rating Scale (BPRS) (Fig. S2) . The behavioral assessments in the MDD participants will be investigated in future reports once a larger cohort is enrolled. 13 C MRS acquisition and processing MRS data were acquired on a 4.0 T whole-body magnet interfaced to a Bruker AVANCE spectrometer (Bruker Instruments, Billerica, MA, USA). Subjects were placed supine in the magnet, with their head immobilized with foam. An RF probe consisting of one circular 13 C coil (8.5 cm ∅) and two circular, quadrature-driven 1 H RF coils (12.5 cm ∅) were used for acquisition of 13 C MR spectra from the frontal lobe (Fig. 1a, b) . Following tuning and acquisition of scout images, second-order shimming of the region of interest (ROI) was performed using phase mapping provided by Bruker. 13 C MR spectra were acquired with a pulse-acquire sequence using an adiabatic 90°excitation pulse and optimized repetition time. Nuclear Overhauser enhancement (nOe) was achieved by applying 1 H block pulses before the 13 C excitation pulse. 1 H decoupling during acquisition consists of pseudo noise decoupling as described by Li et al. [12] , to decouple the long-range 1 H- 13 C coupling of the carboxylic carbon positions. The pseudo noise decoupling pulse has a constant amplitude and the phase of each 1.2-ms unit pulse is randomly assigned to either 0°or 180°. Following the start of [U 13 C]-glucose infusion, 6.5-min blocks of MR spectra were acquired for 120 min (Figs. 1c and S1 ). In the last 60 min of acquisition, we alternated 6.5-min blocks of acquisition using our standard parameters with acquisition without nOe and a 30 s delay in order to obtain a correction for nOe efficiency and saturation effects.
Spectral data were analyzed with −2/6 Hz Lorentzian-toGaussian conversion and 16-fold zero-filing followed by Fourier transformation. An Linear Combination (LC) model approach was used to fit the peak areas of the labeled carbon positions of glutamate C45 and glutamine C45 (Fig. 1c) , which overlapped with aspartate C34. Due to the overlap, we analyzed the combined aspartate and glutamate peaks. However, it is unlikely that the surge in glutamine enrichment was affected by changes in aspartate during ketamine considering that the kinetics of aspartate labeling closely track that of its glutamate precursor [27] , which was not shown to be affected by ketamine infusion. The amplitude of 13 C-labeling over early time points (approximately 20 min) was averaged and normalized by labeling over the steady-state amplitude of the 13 C enrichment time course (post-90 min). This procedure provided a normalized measure of 13 C glutamate and 13 C glutamine enrichment, which reflects the enrichment rate of these metabolites early during the infusion of placebo and ketamine. Cramer-Rao Lower Bounds were used to estimate the quality of the individual measurements, averaging 3% for glutamate and 11% for glutamine. To ensure that the observed 13 C enrichment values are not affected by variability in input glucose enrichment, plasma fractional enrichment (FE) of 13 C glucose was determined during placebo (early FE = 51.2%; steady state FE = 61.1%) and ketamine (early FE = 51.6%; steady state FE = 61.8%), which did not differ between sessions (p > 0.2). To provide an estimate of the variability of the 13 C MRS measures between sessions, we computed the ratio of the mean over the standard deviation of each of the measures across all 21 subjects during the placebo scans. We found relatively low variability, with ratios of 7.3 for 13 C glutamine enrichment and 11 for 13 C glutamate enrichment. The ratios were comparable across healthy (7 for 13 C glutamine and 11 for 13 C glutamate) and depressed subjects (8 for 13 C glutamine and 10 for 13 C glutamate).
Statistical analyses
Before conducting each analysis, the distributions of outcome measure were examined. Estimates of variation are provided
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as standard error of mean (SEM). Considering that this is a first-inhuman study, this study should be considered a first-level pilot study implementing a novel technique, rather than a confirmatory study. Effect sizes are provided as Cohen's d. All tests are 2-tailed with significance set at p ≤ 0.05. The percent change of 13 C glutamate and 13 C glutamine enrichment during ketamine compared to placebo was computed and represented the primary outcome measures. One sample ttests examined whether the percent changes of each metabolite were statistically significant. Follow-up analysis used independent t-tests to determine whether the percent changes of each metabolite differed between the study groups. Spearman's correlations examined the relationship between the metabolites enrichment and psychotomimetic effects of ketamine as determined by CADSS and BPRS in healthy participants.
RESULTS
A total of 21 participants (14 healthy and 7 MDD) successfully completed both study sessions [mean (SEM) age = 30 (1.2) years; 15 males]. In the MDD group, the baseline MADRS was 27 ± 1.8 (mean ± SEM), and three subjects were on a stable antidepressant treatment. As described in "Methods", the full assessment of the behavioral (antidepressant/psychotomimetic) effects of ketamine in the MDD group, and their association with 13 C enrichment, will be investigated in future reports with a larger cohort currently being recruited and studied.
Ketamine effects on glutamine and glutamate enrichment To assess the presence of a glutamate surge, we compared early time points of the enrichment of glutamate and glutamine between the placebo and ketamine groups. This period was comparable to that studied previously by 13 C MRS in rodent models [16, 17] . In the current study, the 13 C glutamine enrichment was 13% greater during ketamine infusion than with placebo (t = 2.4, df = 20, p = 0.02; Fig. 3 ), but no significant effect of ketamine on 13 C glutamate enrichment was seen (t = 0.2, df = 20, p = 0.81; Fig. 3 ). To examine whether the cycling surge differed in MDD, we conducted an exploratory analysis, which showed a comparable effect size in healthy (d = 0.48) and MDD (d = 0.78), with no statistically significant differences between groups (p = 0.85; Fig. 4 ). 
DISCUSSION
The study results provide the most direct evidence yet in humans of a ketamine-induced increase in prefrontal glutamate release, based on the detection of increased 13 C labeling of glutamine. The rapid initial labeling of glutamine is consistent with previous findings in preclinical models. Comparable to preclinical findings with 13 C MRS [17] , the changes in 13 C-glutamine (13%) were more prominent than 13 C-glutamate (1%). Given the exponential Fig. 3 Effects of ketamine on prefrontal glutamate-glutamine cycling and neuroenergetics. In the first 20 min post infusion, ketamine induced a rapid increase in 13 C-glutamine enrichment, indicating an acute surge in prefrontal glutamate-glutamine cycling. The enrichment of 13 C-glutamate remained stable, suggesting no changes in oxidative energy production early during ketamine infusion Fig. 4 Separate effects of ketamine on prefrontal glutamate-glutamine cycling and neuroenergetics in healthy and major depressive disorder (MDD) subjects. a Mean and SEM of 13 C-glutamate and 13 C-glutamine during placebo (Plc) and during ketamine (Ket). b Individual values, as well as mean and SEM, of percent change in enrichment of 13 C-glutamine during ketamine compared to placebo in each group. The pattern of changes in 13 C-glutamine and 13 C-glutamate enrichments was comparable between healthy and depressed subjects, with no statistically significant differences between the two groups. The similarities indicate that while the impacts of ketamine on glutamate-glutamine cycling were significant, both groups were affected to about the same extent
The effects of ketamine on prefrontal glutamate neurotransmission in. . . CG Abdallah et al. decrease in ketamine levels after injection, ketamine and norketamine brain levels during infusions in humans are likely to resemble the immediate time period post-injection in rodents, in which there was no significant increase in 13 C glutamate enrichment (also~1%). The previous 13 C MRS work with rodents also examined a set of animals in which 13 C administration was begun with an 18-min delay after ketamine administration, and in that condition the increase in 13 C glutamate was more apparent, though still less than glutamine.
The ketamine-induced acute glutamate surge also plays an important role in the psychotomimetic effects of the drug, behavioral alterations that are believed to capture core phenomenology of the pathophysiology of schizophrenia [28] . Lacking a direct measure of glutamate neurotransmission in vivo, investigators over the past two decades have employed several elegant approaches to infer the presence of a ketamine-induced glutamate surge in humans and to relate this surge to its psychotomimetic effects. Early studies have shown that inhibitors of glutamate release attenuate the ketamine-induced psychotomimetic symptoms [20] [21] [22] [23] . Other studies have employed pharmacoimaging paradigms to demonstrate a relationship between ketamine-induced prefrontal activation/connectivity and its transient behavioral disturbances [29] [30] [31] [32] [33] [34] [35] [36] , or to block prefrontal activation/connectivity using glutamate inhibitors [20, 37] . More recently, a metabotropic glutamatergic receptor tracer was also used to explore the acute effects of ketamine [38] [39] [40] .
1 H MRS, a method capable of estimating total-but not dynamic cycling of-prefrontal glutamate and glutamine levels show changes in tissue content of glutamate and/or glutamine during ketamine infusion [32, [41] [42] [43] , but also see [44] . Together, the data provided indirect evidence supporting the presence of a ketamine-induced surge in glutamate neurotransmission in humans and that this surge may be associated with the psychotomimetic effects of the drug.
While underscoring the pilot nature of the correlation analyses in the current report, it is intriguing that CADSS scores significantly correlated with glutamate/glutamine ratio (r = −0.54, n = 14, p = 0.048; Cohen's d = 1.3), but not with glutamine enrichment (r = −0.38, n = 14, p = 0.19; Cohen's d = 0.8). A possible explanation is that the low glutamate/glutamine enrichment ratio reflects low EPC. In this model, healthy individuals with high sensitivity to ketamine (i.e., NMDAR hypofunction) would have higher blockade of synaptic NMDAR, leading to reduced postsynaptic activation per glutamate cycle, and subsequent increase in psychotomimetic symptoms. This hypothesis could be assessed in future 13 C MRS studies enrolling larger sample of healthy individuals with variable sensitivity to ketamine (e.g., with/without family history of alcoholism [45, 46] ), as well as by testing the ability of NMDAR agonists to affect the 13 C glutamate/glutamine ratio. The approach parallels extent preclinical data [16, 17] , which facilitates the translatability of the biomarker between species.
Limitations Thus far, this study provided first-level pilot evidence about the potential utility of the 13 C MRS pharmacoimaging paradigm in human models of schizophrenia, demonstrating the longhypothesized ketamine-induced glutamate surge and presenting pilot evidence associating the psychotomimetic effects of ketamine with reduced EPC, as estimated by the 13 C glutamate/ glutamine ratio. However, considering the pilot nature of the association findings, and the lack of direct modulation implicating NMDAR hypofunction in the variability of 13 C glutamate/glutamine ratio, future replications and laboratory testing are required. To assess the psychotomimetic effects in the healthy group, we administered a larger dose along with a bolus. Future studies aiming to compare neurotransmission changes between healthy and depressed groups would require administering the same doses in both population. Other limitations include the small sample size, which requires replication in larger studies, and the fixed-order acquisition, which requires future test-retest reliability data or randomized parallel groups design. Moreover, the overlap between glutamine and aspartate peaks prevented the individual fitting of aspartate and glutamine. Finally, due to limitations that may include biological variability and low spatial resolution of 13 C MRS, the application of the 13 C-glutamate/glutamine ratio may be limited to alterations in glutamate neurotransmission in groups of individuals or within subjects. However, new higher spatial resolution 1 H- 13 C MRS methods that can measure glutamate and glutamine, without aspartate, may allow application to evaluate individual subject responses in the future [47] .
Preclinical studies have found that the NMDAR antagonist ketamine blocks glutamate neurotransmission, but only at high anesthetic doses [48] . At subanesthetic doses, ketamine induces a paradoxical increase in glutamate neurotransmission [14, 49] . The acute surge in glutamate transmission increases prefrontal synaptic connectivity, through enhanced activity-dependent brain-derived neurotrophic factor (BDNF) and related downstream signaling [14] . Other putative RAADs (e.g., scopolamine and (2R,6R)-Hydroxynorketamine) show a comparable acute surge in prefrontal glutamate [17, [50] [51] [52] [53] and enhanced BDNF signaling Fig. 5 Association between glutamate neurotransmission and the psychotomimetic effects of ketamine in healthy participants. a Reduced neuroenergetics relative to neurotransmitter cycling, as measured by the 13 C-glutamate/ 13 C-glutamine ( 13 C Glu/Gln) ratio, is associated with the psychotomimetic effects of ketamine, as measured by the Clinician-Administered Dissociative States Scale (CADSS). b The association with the Brief Psychiatric Rating Scale (BPRS) positive symptoms was comparable in effect size, but did not reach statistical significance in this sample of 14 subjects
The effects of ketamine on prefrontal glutamate neurotransmission in. . . CG Abdallah et al. [54, 55] . Together, the preclinical evidence to date underscores the critical role of acute prefrontal glutamate neurotransmission in the mechanism of action of various RAADs. It also highlights the role of prefrontal synaptic plasticity-i.e., the increased density and connectivity evident at 24 h post treatment and lasting for a week [4, 56] . In humans, functional global brain connectivity was previously used to provide a well-replicated evidence of reduced prefrontal connectivity in individuals with MDD [37, [57] [58] [59] , a dysconnectivity that is normalized 24 h post-ketamine treatment [37, 57] . The ketamine-induced subacute increases in prefrontal connectivity were positively associated with the antidepressant response [57] . In healthy subjects, a direct link between prefrontal connectivity and glutamate neurotransmission was demonstrated, while showing an acute ketamine-induced surge in prefrontal connectivity, which is attenuated by a glutamate inhibitor [37] . Together, the human evidence is consistent with the findings from preclinical models, with particular focus on the essential role of acute and subacute prefrontal synaptic neurotransmission and connectivity in the mechanism of ketamine and perhaps other RAADs.
In this context, the 13 C MRS pharmacoimaging paradigm and findings offer the following evidence and possibilities: (1) It is consistent with the occurrence of an acute ketamine-induced glutamate surge in humans, using a paradigm that is readily translated between animals and humans. (2) The similar time frames between preclinical observations with human connectivity and neurotransmitter cycling data raises the question whether acute increases in glutamate-glutamine cycling would predict the antidepressant effects of ketamine, comparable to findings from preclinical and connectivity data. (3) The findings, taken together with published observations, suggest the possibility of a positive relationship between prefrontal glutamate cycling and global connectivity. Such data would not only inform us about the mechanisms of RAADs, but also provide important information about the interplay between molecular neurotransmission and large-scale intrinsic networks in the human brain. (4) It may be that cycling and connectivity measures could facilitate the optimization of antipsychotics and RAADs doses prior to testing in costly clinical trials. Taken together, these points raise the possibility of application as rigorous and reproducible biomarkers of treatment target engagement and validation to improve the development of novel antipsychotics and RAADs.
